Online citations, reference lists, and bibliographies.
← Back to Search

Paralisi Sopranucleare Progressiva (malattia Di Steele-Richardson-Olszewski)

F. Dubas, J. Cassereau, P. Lejeune
Published 2007 · Art

Cite This
Download PDF
Analyze on Scholarcy
Share
La paralisi sopranucleare progressiva (PSP o malattia di Steele-Richardson-Olszewski) e la seconda causa in ordine di frequenza di parkinsonismo, dopo la morbo di Parkinson. L’eta di esordio media e di 60 anni. E caratterizzata da acinesia assiale, paralisi della verticalita dello sguardo, distonia cervicale in estensione, sindrome pseudobulbare e sindrome sotto-corticofrontale. La conferma della diagnosi spetta allo studio neuropatologico, con una perdita neuronale e degenerazioni neurofibrillari del tronco cerebrale.
This paper references
Dopa-unresponsive pure akinesia or freezing. A condition within a wide spectrum of PSP?
H. Imai (1993)
10.1007/s100720070056
A case of spontaneous arm levitation in progressive supranuclear palsy
D. I. Gunal (2000)
10.1034/j.1600-0404.2001.103002123.x
Donepezil in the treatment of progressive supranuclear palsy
G. Fabbrini (2001)
10.1212/WNL.52.4.879
Arm levitation in progressive supranuclear palsy
C. Barclay (1999)
10.1002/ANA.410150130
Apraxia of eyelid opening in progressive supranuclear palsy
I. Dehaene (1984)
Cerebral perfusion in progressive supranuclear palsy.
K. Johnson (1992)
10.1016/0022-510X(71)90029-3
Progressive supranuclear palsy (the Steele-Richardson-Olszewski syndrome). A report of 9 cases with particular reference to the mechanism of the oculomotor disorder.
M. Dix (1971)
10.1001/ARCHNEUR.1991.00530160057013
Positron emission tomography in progressive supranuclear palsy.
M. Bhatt (1991)
[Steele-Richardson-Olszewski disease without ophthalmoplegia. 6 clinico-anatomic cases].
F. Dubas (1983)
10.1136/jnnp.54.2.159
Diffuse Lewy body disease presenting with a supranuclear gaze palsy.
J. Fearnley (1991)
La paralysie supra-nucléaire progressive. A propos d'une observation anatomo-clinique.
J. Cambier (1969)
[Frontal syndrome of progressive supranuclear palsy].
J. Cambier (1985)
10.1007/s004010050706
Progressive supranuclear palsy with palatal myoclonus
N. Suyama (1997)
Neuropathologie des syndromes parkinsoniens.
F. Gray (1988)
10.1016/0304-3940(92)90643-L
Clinical and pathological study of two patients with progressive supranuclear palsy and Alzheimer's changes. Antigenic determinants that distinguish cortical and subcortical neurofibrillary tangles
F. cruz-Sánchez (1992)
10.1093/BRAIN/120.1.75
Apraxia in Parkinson's disease, progressive supranuclear palsy, multiple system atrophy and neuroleptic-induced parkinsonism.
R. Leiguarda (1997)
10.1007/BF00230481
Neurofibrillary tangles in the neurons of spinal dorsal root ganglia of patients with progressive supranuclear palsy
M. Nishimura (2004)
10.1001/ARCHNEUR.1995.00540270090024
Some specific clinical features differentiate multiple system atrophy (striatonigral variety) from Parkinson's disease.
C. Colosimo (1995)
[2 cases of isolated dystonia of the upper limb as an early sign of Steele-Richardson-Olszewski disease].
J. Léger (1987)
10.1046/j.1471-4159.1999.0721243.x
Neurofibrillary Degeneration in Progressive Supranuclear Palsy and Corticobasal Degeneration
N. Sergeant (1999)
10.1002/MDS.870070410
Diffuse lewy body disease presenting with supranuclear gaze palsy, parkinsonism, and dementia: A case report
V. M. D. de Bruin (1992)
10.1212/WNL.35.8.1189
Treatment of progressive supranuclear palsy with tricyclic antidepressants
G. Newman (1985)
10.1001/ARCHNEUR.62.9.1444
A New Mutation of the τ Gene, G303V, in Early-Onset Familial Progressive Supranuclear Palsy
R. Ros (2005)
10.1016/0022-510X(71)90056-6
Die bangsche krankheit und das periphere nervensystem
E. J. Field (1971)
10.1007/BF00703207
Unusual paired helical filaments in progressive supranuclear palsy
S. Takauchi (2004)
10.1212/WNL.37.4.570
Progressive supranuclear palsy and a multi‐infarct state
R. Dubinsky (1987)
10.1016/S0161-6420(79)35498-7
The eye movement disorders of progressive supranuclear palsy.
F. Chu (1979)
10.1111/j.1750-3639.1999.tb00549.x
Tau‐positive dial Inclusions in Progressive Supranuclear Palsy, Corticobasal Degeneration and Pick's Disease
T. Komori (1999)
Apport de l'IRM pour le diagnostic de l'atrophie multisystématisée
E. Broussolle (2002)
10.1212/WNL.41.1.25
Mesencephalic cholinergic nuclei in progressive supranuclear palsy
J. Juncos (1991)
10.1111/j.1600-0404.1985.tb03186.x
Progressive supranuclear palsy ‐ 20 years later
M. Kristensen (1985)
10.1212/01.WNL.0000165977.38272.15
“Applause sign” helps to discriminate PSP from FTD and PD
B. Dubois (2005)
[Obsessive-compulsive behavior and progressive supranuclear palsy].
A. Destée (1990)
[Deglutition disorders and progressive supra nuclear paralysis. Value of subcutaneous administration of apomorphine].
P. Brocker (1991)
10.1136/jnnp.62.4.352
Dystonia in progressive supranuclear palsy.
C. Barclay (1997)
10.1016/S0022-510X(00)00480-9
Diagnostic significance of tau protein in cerebrospinal fluid from patients with corticobasal degeneration or progressive supranuclear palsy
K. Urakami (2001)
[Progressive supranuclear paralysis. Anatomical and clinical observation].
J. Cambier (1969)
10.1136/jnnp.37.2.121
The `subcortical dementia' of progressive supranuclear palsy
M. Albert (1974)
10.1212/WNL.31.12.1507
Progressive supranuclear palsy
R. Rafal (1981)
10.1007/s004010051052
A mutation at codon 279 (N279K) in exon 10 of the Tau gene causes a tauopathy with dementia and supranuclear palsy
M. Delisle (1999)
10.1093/BRAIN/108.3.785
Subcortical dementia. Frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy.
R. D'antona (1985)
10.1002/ANA.410250205
Positron tomography demonstrates frontal lobe hypometabolism in progressive supranuclear palsy
A. Goffinet (1989)
10.1212/WNL.46.4.922
Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
I. Litvan (1996)
Progressive supranuclear palsy: motor, neurobehavioral, and neuro-ophthalmic findings.
J. Jankovic (1990)
10.1212/WNL.41.7.986
Idazoxan treatment in progressive supranuclear palsy
J. Ghika (1991)
10.1093/HMG/8.4.711
Association of an extended haplotype in the tau gene with progressive supranuclear palsy.
M. Baker (1999)
10.1001/ARCHNEUR.1973.00490290064007
Ultrastructure of neurofibrillary tangles in Steele-Richardson-Olszewski syndrome.
I. Tellez-Nagel (1973)
10.1001/ARCHNEUR.1988.00520350032011
Slowing of cognitive processing in progressive supranuclear palsy. A comparison with Parkinson's disease.
B. Dubois (1988)
10.1093/BRAIN/122.7.1233
Clinical genetics of familial progressive supranuclear palsy.
A. Rojo (1999)
10.1093/BRAIN/AWH488
Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism.
D. Williams (2005)
10.1002/ANA.410130211
Immunocytochemical comparison of neurofibrillary tangles in senile dementia of Alzheimer type, progressive supranuclear palsy, and postencephalitic parkinsonism
S. Yen (1983)
10.1001/ARCHNEUR.1964.00460160003001
PROGRESSIVE SUPRANUCLEAR PALSY. A HETEROGENEOUS DEGENERATION INVOLVING THE BRAIN STEM, BASAL GANGLIA AND CEREBELLUM WITH VERTICAL GAZE AND PSEUDOBULBAR PALSY, NUCHAL DYSTONIA AND DEMENTIA.
J. Steele (1964)
10.1093/BRAIN/111.3.615
Steele-Richardson-Olszewski syndrome. Brain energy metabolism, blood flow and fluorodopa uptake measured by positron emission tomography.
K. Leenders (1988)
10.1002/1531-8249(20010201)49:2<263::AID-ANA50>3.0.CO;2-K
Familial atypical progressive supranuclear palsy associated with homozigosity for the delN296 mutation in the tau gene
P. Pastor (2001)
10.1002/ANA.410310209
Striatal D2 receptor status in patients with Parkinson's disease, striatonigral degeneration, and progressive supranuclear palsy, measured with 11C‐raclopride and positron emission tomography
D. Brooks (1992)
10.1002/ANA.410410222
Genetic evidence for the involvement of τ in progressive supranuclear palsy
C. Conrad (1997)
10.1016/0013-4694(80)90226-6
Etude du sommeil dans la paralysie supra-nucleaire progressive
J. Perret (1980)
10.1136/bmj.310.6977.447
Fortnightly Review: Parkinsonism—recognition and differential diagnosis
N. Quinn (1995)
10.1002/MDS.870130116
Increased cerebrospinal fluid levels of neurofilament protein in progressive supranuclear palsy and multiple‐system atrophy compared with Parkinson's disease
B. Holmberg (1998)
Progressive supranuclear palsy: anatomoclinical and biochemical considerations.
Y. Agid (1987)
10.1093/BRAIN/123.5.880
Progressive supranuclear palsy pathology caused by a novel silent mutation in exon 10 of the tau gene
P. M. Stanford (2000)
10.1136/jnnp.51.9.1224
A case of progressive subcortical gliosis presenting clinically as Steele-Richardson-Olszewski syndrome.
R. Will (1988)
10.1136/jnnp.50.9.1197
Rigidity and dorsiflexion of the neck in progressive supranuclear palsy and the interstitial nucleus of Cajal.
J. Fukushima-Kudo (1987)
10.1055/S-2001-13118
Diagnosis and management of progressive supranuclear palsy.
I. Litvan (2001)
10.1001/ARCHNEUR.58.7.1076
Measurement of the midbrain diameter on routine magnetic resonance imaging: a simple and accurate method of differentiating between Parkinson disease and progressive supranuclear palsy.
M. Warmuth-Metz (2001)
10.1016/S0035-3787(05)85030-1
Apport de l’IRM pour le diagnostic de paralysie supranucléaire progressive
M. Vérin (2005)
10.1007/s007020070006
Magnetic resonance imaging distinguishes progressive supranuclear palsy from multiple system atrophy
R. Asato (2000)
10.1212/WNL.38.7.1031
Prevalence and natural history of progressive supranuclear palsy
L. Golbe (1988)
10.1093/BRAIN/AWF109
Pathological, clinical and genetic heterogeneity in progressive supranuclear palsy.
H. Morris (2002)
10.1001/ARCHNEUR.1993.00540050063017
Multiple system atrophy and progressive supranuclear palsy. Diminished striatal D2 dopamine receptor activity demonstrated by 123I-IBZM single photon emission computed tomography.
E. V. van Royen (1993)
10.1002/ANA.410250609
Sleep abnormalities in progressive supranuclear palsy
M. Aldrich (1989)
10.1016/S0140-6736(99)04137-9
Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study
A. Schrag (1999)
10.1016/S0140-6736(85)92470-5
PROGRESSIVE SUPRANUCLEAR PALSY: LOSS OF STRIATAL DOPAMINE RECEPTORS DEMONSTRATED IN VIVO BY POSITRON TOMOGRAPHY
J. Baron (1985)
10.1002/ANA.410320516
Dopamine D1 and D2 receptors in progressive supranuclear palsy: An autoradiographic study
J. Pascual (1992)
10.1001/ARCHNEUR.1990.00530050077015
Frontal lobe function in progressive supranuclear palsy.
J. Grafman (1990)
[Parkinsonian features of Steele-Richardson-Olszewski syndrome].
G. Fénelon (1993)
10.1001/ARCHNEUR.62.9.1453
Clinical and pathologic evidence of corticobasal degeneration and progressive supranuclear palsy in familial tauopathy.
P. Tuite (2005)
10.1016/S1353-8020(00)00083-3
CSF-neurofilament and levodopa tests combined with discriminant analysis may contribute to the differential diagnosis of Parkinsonian syndromes.
B. Holmberg (2001)
10.1212/WNL.47.1.1
Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome)
I. Litvan (1996)
10.1212/WNL.37.9.1546
Limb dystonia in progressive supranuclear palsy
R. Rafal (1987)
10.1136/jnnp.55.3.181
Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases.
A. Hughes (1992)
10.1136/jnnp.66.5.665
The tau gene A0 polymorphism in progressive supranuclear palsy and related neurodegenerative diseases
H. Morris (1999)
10.1007/BF00427214
Distribution of cortical neurofibrillary tangles in progressive supranuclear palsy: A quantitative analysis of six cases
P. Hof (2004)
10.1001/ARCHNEUR.1990.00530070035009
Positron emission tomography study in progressive supranuclear palsy. Brain hypometabolic pattern and clinicometabolic correlations.
J. Blin (1990)
10.1002/ANA.410240309
Alz 50 recognizes abnormal filaments in Alzheimer's disease and progressive supranuclear palsy
Massimo Tabatonm (1988)
10.1007/BF00687231
Neurofibrillary pathology in progressive supranuclear palsy
N. Ghatak (2004)
10.1212/WNL.41.5.634
Severity and specificity of cognitive impairment in Alzheimer's, Huntington's, and Parkinson's diseases and progressive supranuclear palsy
B. Pillon (1991)
10.1212/WNL.56.7.957
Comparison of apraxia in corticobasal degeneration and progressive supranuclear palsy
V. Pharr (2001)
10.1136/jnnp.48.12.1234
Cognitive deficits in the Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy).
E. Maher (1985)
10.1002/ANA.410240308
Cerebral hypometabolism in progressive supranuclear palsy studied with positron emission tomography
N. Foster (1988)
10.1016/0006-8993(87)90697-4
Brain neuropeptides in progressive supranuclear palsy
H. Taquet (1987)
10.1002/ANA.410180503
Dopaminergic and cholinergic lesions in progressive supranuclear palsy
M. Ruberg (1985)
10.1002/MDS.870040402
Eyelid movement abnormalities in progressive supranuclear palsy
Lawrence I. Golbe (1989)



Semantic Scholar Logo Some data provided by SemanticScholar